IVCY was administered at 0.5 g/m2 every monthly during induction remission therapy at our faculty, and the IVCY dose was reduced to 75–50% for MPA patients who have kidney failure according to the Japanese patients with MPO-ANCA-associated vasculitis study27. The gene discussed is MPO; the disease is kidney failure.